title: Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma.
abstract: Canine hemangiosarcoma (HSA) is a neoplasm of vascular endothelial origin that has an aggressive biological behaviour, with less than 10% of dogs alive at 12-months postdiagnosis. Treatment of choice consists of surgery followed by adjuvant doxorubicin-based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). Twenty-seven dogs were enrolled; following staging work-up, 18 were treated with AC and 9 with ADTIC. Median TTM and survival time were longer for dogs treated with ADTIC compared with those receiving AC (>550 versus 112 days, P = 0.021 and >550 versus 142 days, P = 0.011, respectively). Both protocols were well tolerated, without need for dose reduction or increased interval between treatments. A protocol consisting of combined doxorubicin and dacarbazine is safe in dogs with HSA and prolongs TTM and survival time.
authors.affiliation: Department of Veterinary Clinics, Small Animal Teaching Hospital, University of Pisa, Pisa, Italy.|Division of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Finotello
authors.affiliation: Department of Veterinary Science and Public Health, University of Milan, Milan, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Stefanello
authors.affiliation: Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.|Department of Animal Medicine, Production and Health, University of Padova, Padova, Italy.|Istituto Veterinario di Novara, Granozzo con Monticello, Novara, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Zini
authors.affiliation: Centro Oncologico Veterinario, Bologna, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Marconato
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003606:Dacarbazine / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000662:veterinary*; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide
keywords: cyclophosphamide; dacarbazine; dog; doxorubicin; hemangiosarcoma